1:06
0
PINCLINICAL IMPACT Series
CLINICAL IMPACT - Ask the experts: Tumor microenvironment in breast cancer
ASCO 2024 - Current State of Adjuvant Therapy Strategies: Consider Subtype, Nodal Involvement, Residual Risk
ASCO 2024 - Complete program listing (16 programs)
Dr. Tarantino - DESTINY BREAST
Q1: In which patient profiles would you consider standard of care T-DXd for in the 2L HER2+ mBC setting? And is there a patient profile you would not consider it?
ASCO 2024 - Abemaciclib After Progression on Prior CDK4/6 Inhibition Improved PFS in HR+/HER2- Advanced Breast Cancer
ESMO 2024 - Complete program listing (14 programs)
Dr. Tarantino - DESTINY BREAST
Q2: What are the steps you take to optimally manage ILD for patients on T-DXd (The 5 S Rules)?
Latest News and Editorial
